Back to Search Start Over

Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998–2020)

Authors :
Palmer Masumbe Netongo
Jude D. Bigoga
Anthony Ajua
Alexis Tourgordi
Wilfred Fon Mbacham
Jean Paul Chedjou
Akindeh M. Nji
Innocent Mbulli Ali
Barbara Atogho-Tiedeu
Olivia A. Achonduh-Atijegbe
Carole Else Eboumbou Moukoko
Pascal Ringwald
Oliva Ebie Ndum
Marcel N. Moyeh
Rose G. F. Leke
Dorothy A. Fosah
Rosine Djokam-Dadjeu
Fon Abongwa Acho
Eric A. Achidi
Peter Thelma Ngwa Niba
Esther Tallah
Cyrille Mbanwi Mbu’u
Marie-Solange Evehe
Randolph Ngwafor
Michael Alifrangis
Lesley Ngum Ngum
Source :
Niba, P T N, Nji, A M, Evehe, M-S, Ali, I M, Netongo, P M, Ngwafor, R, Moyeh, M N, Ngum, L N, Ndum, O E, Acho, F A, Mbu'u, C M, Fosah, D A, Atogho-Tiedeu, B, Achonduh-Atijegbe, O, Djokam-Dadjeu, R, Chedjou, J P K, Bigoga, J D, Moukoko, C E E, Ajua, A, Achidi, E, Tallah, E, Leke, R G F, Tourgordi, A, Ringwald, P, Alifrangis, M & Mbacham, W F 2021, ' Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon : a systematic review and meta-analysis (1998-2020) ', Malaria Journal, vol. 20, 32 . https://doi.org/10.1186/s12936-020-03543-8, Malaria Journal, Vol 20, Iss 1, Pp 1-20 (2021), Malaria Journal
Publication Year :
2021
Publisher :
Springer Science and Business Media LLC, 2021.

Abstract

Background Malaria remains highly endemic in Cameroon. The rapid emergence and spread of drug resistance was responsible for the change from monotherapies to artemisinin-based combinations. This systematic review and meta-analysis aimed to determine the prevalence and distribution of Plasmodium falciparum drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon from January 1998 to August 2020. Methods The PRISMA-P and PRISMA statements were adopted in the inclusion of studies on single nucleotide polymorphisms (SNPs) of P. falciparum anti-malarial drug resistance genes (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, Pfatp6, Pfcytb and Pfk13). The heterogeneity of the included studies was evaluated using the Cochran’s Q and I2 statistics. The random effects model was used as standard in the determination of heterogeneity between studies. Results Out of the 902 records screened, 48 studies were included in this aggregated meta-analysis of molecular data. A total of 18,706 SNPs of the anti-malarial drug resistance genes were genotyped from 47,382 samples which yielded a pooled prevalence of 35.4% (95% CI 29.1–42.3%). Between 1998 and 2020, there was significant decline (P Pfcrt 76 T (79.9%-43.0%), Pfmdr1 86Y (82.7%-30.5%), Pfdhfr 51I (72.2%-66.9%), Pfdhfr 59R (76.5%-67.8%), Pfdhfr 108 N (80.8%-67.6%). The only exception was Pfdhps 437G which increased over time (30.4%-46.9%, P Pfdhps 540E that remained largely unchanged (0.0%-0.4%, P = 0.201). Exploring mutant haplotypes, the study observed a significant increase in the prevalence of Pfcrt CVIET mixed quintuple haplotype from 57.1% in 1998 to 57.9% in 2020 (P Pfdhfr IRN mutant haplotype (66.2% to 67.3%, P = 0.427). The Pfk13 amino acid polymorphisms associated with artemisinin resistance were not detected. Conclusions This review reported an overall decline in the prevalence of P. falciparum gene mutations conferring resistance to 4-aminoquinolines and amino alcohols for a period over two decades. Resistance to artemisinins measured by the presence of SNPs in the Pfk13 gene does not seem to be a problem in Cameroon. Systematic review registration PROSPERO CRD42020162620

Details

ISSN :
14752875
Volume :
20
Database :
OpenAIRE
Journal :
Malaria Journal
Accession number :
edsair.doi.dedup.....5f6fe37c1d6b43b672f9b8d0bffee2c9
Full Text :
https://doi.org/10.1186/s12936-020-03543-8